
MIRM Stock Forecast & Price Target
MIRM Analyst Ratings
Bulls say
Mirum Pharmaceuticals Inc. reported net sales revenue of $64.1 million for LIVMARLI in the fourth quarter of 2024, reflecting an 8.4% growth from the previous quarter and a substantial 54.5% increase from the fourth quarter of 2023. The company anticipates continued growth in LIVMARLI's net sales, particularly from the progressive familial intrahepatic cholestasis (PFIC) indication, which is expected to contribute an estimated $15 million in revenue for the full year of 2025. Additionally, the promising interim results from the VANTAGE study for volixibat highlight the potential for further market expansion and positive cash flow, bolstering confidence in Mirum’s financial outlook and growth prospects.
Bears say
Mirum Pharmaceuticals faces significant financial risks that contribute to a negative outlook on its stock, including the potential for sales growth of its primary products, Livmarli and volixibat, to fall well below expectations. The company reported a FY2024 net loss of $87.9 million, driven by substantial operating expenses totaling $140.6 million in research and development and $202.2 million in selling, general, and administrative costs, which may necessitate additional capital raising and lead to share dilution. Moreover, challenges related to regulatory approvals, trial results, and the competitive landscape for its pipeline candidates could hinder commercial uptake, delaying any path to profitability and exacerbating financial instability.
This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIRM Analyst Forecast & Price Prediction
Start investing in MIRM
Order type
Buy in
Order amount
Est. shares
0 shares